Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer

C Arditi; I Peytremann-Bridevaux; B Burnand; V F Eckardt; P Bytzer; L Agréus; R W Dubois; J-P Vader; F Froehlich; V Pittet; S Schusselé Filliettaz; P Juillerat; J-J Gonvers; EPAGE II Study Group

doi:10.1055/s-0028-1119626

Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer

C Arditi, I Peytremann-Bridevaux, B Burnand, V F Eckardt, P Bytzer, L Agréus, R W Dubois, J-P Vader, F Froehlich, V Pittet, S Schusselé Filliettaz, P Juillerat, J-J Gonvers, EPAGE II Study Group

49 Citations (Scopus)

Abstract

BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for screening for colorectal cancer (CRC) in asymptomatic individuals without personal history of CRC or polyps, and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II. METHODS: A systematic search of guidelines, systematic reviews, and primary studies regarding colonoscopy for screening for colorectal cancer was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy in these circumstances. RESULTS: Available evidence for CRC screening comes from small case-controlled studies, with heterogeneous results, and from indirect evidence from randomized controlled trials (RCTs) on fecal occult blood test (FOBT) screening and studies on flexible sigmoidoscopy screening. Most guidelines recommend screening colonoscopy every 10 years starting at age 50 in average-risk individuals. In individuals with a higher risk of CRC due to family history, there is a consensus that it is appropriate to offer screening colonoscopy at < 50 years. EPAGE II considered screening colonoscopy appropriate above 50 years in average-risk individuals. Panelists deemed screening colonoscopy appropriate for younger patients, with shorter surveillance intervals, where family or personal risk of colorectal cancer is higher. A positive FOBT or the discovery of adenomas at sigmoidoscopy are considered appropriate indications. CONCLUSIONS: Despite the lack of evidence based on randomized controlled trials (RCTs), colonoscopy is recommended by most published guidelines and EPAGE II criteria available online (http://www.epage.ch), as a screening option for CRC in individuals at average risk of CRC, and undisputedly as the main screening tool for CRC in individuals at moderate and high risk of CRC.

Original language	English
Journal	Endoscopy
Volume	41
Issue number	3
Pages (from-to)	200-8
Number of pages	8
ISSN	0013-726X
DOIs	https://doi.org/10.1055/s-0028-1119626
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-0028-1119626

Cite this

Arditi, C., Peytremann-Bridevaux, I., Burnand, B., Eckardt, V. F., Bytzer, P., Agréus, L., Dubois, R. W., Vader, J.-P., Froehlich, F., Pittet, V., Schusselé Filliettaz, S., Juillerat, P., Gonvers, J.-J., & EPAGE II Study Group (2009). Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. Endoscopy, 41(3), 200-8. https://doi.org/10.1055/s-0028-1119626

Arditi, C, Peytremann-Bridevaux, I, Burnand, B, Eckardt, VF, Bytzer, P, Agréus, L, Dubois, RW, Vader, J-P, Froehlich, F, Pittet, V, Schusselé Filliettaz, S, Juillerat, P, Gonvers, J-J & EPAGE II Study Group 2009, 'Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer', Endoscopy, vol. 41, no. 3, pp. 200-8. https://doi.org/10.1055/s-0028-1119626

@article{1b9cbd6073c611df928f000ea68e967b,

title = "Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer",

abstract = "BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for screening for colorectal cancer (CRC) in asymptomatic individuals without personal history of CRC or polyps, and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II. METHODS: A systematic search of guidelines, systematic reviews, and primary studies regarding colonoscopy for screening for colorectal cancer was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy in these circumstances. RESULTS: Available evidence for CRC screening comes from small case-controlled studies, with heterogeneous results, and from indirect evidence from randomized controlled trials (RCTs) on fecal occult blood test (FOBT) screening and studies on flexible sigmoidoscopy screening. Most guidelines recommend screening colonoscopy every 10 years starting at age 50 in average-risk individuals. In individuals with a higher risk of CRC due to family history, there is a consensus that it is appropriate to offer screening colonoscopy at < 50 years. EPAGE II considered screening colonoscopy appropriate above 50 years in average-risk individuals. Panelists deemed screening colonoscopy appropriate for younger patients, with shorter surveillance intervals, where family or personal risk of colorectal cancer is higher. A positive FOBT or the discovery of adenomas at sigmoidoscopy are considered appropriate indications. CONCLUSIONS: Despite the lack of evidence based on randomized controlled trials (RCTs), colonoscopy is recommended by most published guidelines and EPAGE II criteria available online (http://www.epage.ch), as a screening option for CRC in individuals at average risk of CRC, and undisputedly as the main screening tool for CRC in individuals at moderate and high risk of CRC.",

author = "C Arditi and I Peytremann-Bridevaux and B Burnand and Eckardt, {V F} and P Bytzer and L Agr{\'e}us and Dubois, {R W} and J-P Vader and F Froehlich and V Pittet and {Schussel{\'e} Filliettaz}, S and P Juillerat and J-J Gonvers and {EPAGE II Study Group}",

note = "Keywords: Colonoscopy; Colorectal Neoplasms; Europe; Guidelines as Topic; Humans; Randomized Controlled Trials as Topic",

year = "2009",

doi = "10.1055/s-0028-1119626",

language = "English",

volume = "41",

pages = "200--8",

journal = "Endoscopy",

issn = "0013-726X",

publisher = "GeorgThieme Verlag",

number = "3",

}

TY - JOUR

T1 - Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer

AU - Arditi, C

AU - Peytremann-Bridevaux, I

AU - Burnand, B

AU - Eckardt, V F

AU - Bytzer, P

AU - Agréus, L

AU - Dubois, R W

AU - Vader, J-P

AU - Froehlich, F

AU - Pittet, V

AU - Schusselé Filliettaz, S

AU - Juillerat, P

AU - Gonvers, J-J

AU - EPAGE II Study Group

N1 - Keywords: Colonoscopy; Colorectal Neoplasms; Europe; Guidelines as Topic; Humans; Randomized Controlled Trials as Topic

PY - 2009

Y1 - 2009

N2 - BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for screening for colorectal cancer (CRC) in asymptomatic individuals without personal history of CRC or polyps, and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II. METHODS: A systematic search of guidelines, systematic reviews, and primary studies regarding colonoscopy for screening for colorectal cancer was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy in these circumstances. RESULTS: Available evidence for CRC screening comes from small case-controlled studies, with heterogeneous results, and from indirect evidence from randomized controlled trials (RCTs) on fecal occult blood test (FOBT) screening and studies on flexible sigmoidoscopy screening. Most guidelines recommend screening colonoscopy every 10 years starting at age 50 in average-risk individuals. In individuals with a higher risk of CRC due to family history, there is a consensus that it is appropriate to offer screening colonoscopy at < 50 years. EPAGE II considered screening colonoscopy appropriate above 50 years in average-risk individuals. Panelists deemed screening colonoscopy appropriate for younger patients, with shorter surveillance intervals, where family or personal risk of colorectal cancer is higher. A positive FOBT or the discovery of adenomas at sigmoidoscopy are considered appropriate indications. CONCLUSIONS: Despite the lack of evidence based on randomized controlled trials (RCTs), colonoscopy is recommended by most published guidelines and EPAGE II criteria available online (http://www.epage.ch), as a screening option for CRC in individuals at average risk of CRC, and undisputedly as the main screening tool for CRC in individuals at moderate and high risk of CRC.

AB - BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for screening for colorectal cancer (CRC) in asymptomatic individuals without personal history of CRC or polyps, and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II. METHODS: A systematic search of guidelines, systematic reviews, and primary studies regarding colonoscopy for screening for colorectal cancer was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy in these circumstances. RESULTS: Available evidence for CRC screening comes from small case-controlled studies, with heterogeneous results, and from indirect evidence from randomized controlled trials (RCTs) on fecal occult blood test (FOBT) screening and studies on flexible sigmoidoscopy screening. Most guidelines recommend screening colonoscopy every 10 years starting at age 50 in average-risk individuals. In individuals with a higher risk of CRC due to family history, there is a consensus that it is appropriate to offer screening colonoscopy at < 50 years. EPAGE II considered screening colonoscopy appropriate above 50 years in average-risk individuals. Panelists deemed screening colonoscopy appropriate for younger patients, with shorter surveillance intervals, where family or personal risk of colorectal cancer is higher. A positive FOBT or the discovery of adenomas at sigmoidoscopy are considered appropriate indications. CONCLUSIONS: Despite the lack of evidence based on randomized controlled trials (RCTs), colonoscopy is recommended by most published guidelines and EPAGE II criteria available online (http://www.epage.ch), as a screening option for CRC in individuals at average risk of CRC, and undisputedly as the main screening tool for CRC in individuals at moderate and high risk of CRC.

U2 - 10.1055/s-0028-1119626

DO - 10.1055/s-0028-1119626

M3 - Journal article

C2 - 19280531

SN - 0013-726X

VL - 41

SP - 200

EP - 208

JO - Endoscopy

JF - Endoscopy

IS - 3

ER -

Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this